- Home
- GILD vs BMY Comparison
GILD vs BMY Comparison
Compare GILD & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- BMY
- Stock Information
- Founded
- GILD 1987
- BMY 1887
- Country
- GILD United States
- BMY United States
- Employees
- GILD N/A
- BMY N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- GILD Health Care
- BMY Health Care
- Exchange
- GILD Nasdaq
- BMY Nasdaq
- Market Cap
- GILD 129.9B
- BMY 120.5B
- IPO Year
- GILD 1992
- BMY N/A
- Fundamental
- Price
- GILD $110.08
- BMY $48.27
- Analyst Decision
- GILD Buy
- BMY Hold
- Analyst Count
- GILD 25
- BMY 16
- Target Price
- GILD $109.00
- BMY $58.93
- AVG Volume (30 Days)
- GILD 8.8M
- BMY 15.7M
- Earning Date
- GILD 04-24-2025
- BMY 07-25-2025
- Dividend Yield
- GILD 2.87%
- BMY 5.14%
- EPS Growth
- GILD 1118.07
- BMY N/A
- EPS
- GILD 4.73
- BMY 2.67
- Revenue
- GILD $28,735,000,000.00
- BMY $47,636,000,000.00
- Revenue This Year
- GILD $1.54
- BMY N/A
- Revenue Next Year
- GILD $3.70
- BMY N/A
- P/E Ratio
- GILD $23.27
- BMY $18.08
- Revenue Growth
- GILD 4.68
- BMY 4.62
- 52 Week Low
- GILD $62.07
- BMY $39.35
- 52 Week High
- GILD $119.96
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- GILD 58.78
- BMY 49.43
- Support Level
- GILD $107.23
- BMY $46.10
- Resistance Level
- GILD $109.55
- BMY $47.36
- Average True Range (ATR)
- GILD 2.90
- BMY 1.22
- MACD
- GILD 1.01
- BMY 0.43
- Stochastic Oscillator
- GILD 90.02
- BMY 96.49
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.